Determining clinically meaningful change: minimal clinically important difference for common depression scales in

Hossein Soltaninejad1, Ghorban Taghizadeh2, Negin Eissazade3,4

  • 1Department of Occupational Therapy School of Rehabilitation Sciences, Arak University of Medical Sciences, Arak, Iran.

Abstract

Insights

This study establishes Minimal Clinically Important Difference (MCID) values for depression scales in Parkinson's disease (PD). These findings aid in assessing treatment effectiveness for PD patients experiencing depression.

Area of Science:

  • Neuroscience
  • Clinical Psychology
  • Gerontology

Background:

  • The Minimal Clinically Important Difference (MCID) quantifies the smallest patient-perceived beneficial symptom change.
  • MCID values are established for Parkinson's disease (PD) symptoms but are underexplored for depression in PD.

Purpose of the Study:

  • Determine MCID values for the Beck Depression Inventory (BDI-II), Hospital Anxiety and Depression Scale - Depression subscale (HADS-D), and Geriatric Depression Scale (GDS-15) in PD patients.
  • Establish benchmarks for depression assessment in Parkinson's disease.

Main Methods:

  • 112 individuals with PD and depression underwent a 10-week cognitive behavioral therapy program.
  • MCID values were estimated using distribution-based and anchor-based methods, with the Global Rating of Change (GRoC) scale as an anchor.

Main Results:

  • MCID values (mean difference approach) were -5.79 for BDI-II, -3.52 for HADS-D, and -3.05 for GDS-15 (p < 0.001).
  • Optimal MCID cut-offs (Youden's index) were ≤ -3 for BDI-II, ≤ -2 for HADS-D, and ≤ -2 for GDS-15, showing high sensitivity and specificity.

Conclusions:

  • This study provides essential MCID thresholds for depression scales in Parkinson's disease.
  • These benchmarks will enhance clinical decision-making and intervention evaluation for depression in PD.

Related Concept Videos

Depressive Disorders: MDD and Dysthymia01:27

Depressive Disorders: MDD and Dysthymia

Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
547
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
172
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
931
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
214
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
199